Radioimmunodetection of colorectal cancer metastases with 131i-labeled monoclonal antibody b72.3: A pilot study to determine efficacy of detection and pharmacokinetics

H. Stern*, R. Reilly, S. Gallinger, J. Kirsh, C. Deangelis, M. Papa, K. Hay, J. Polihronis, B. Schmoker

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

We performed radioimmunoscintigraphy (RIS) and / or pharmacokinetic (PCK) studies in 12 patients with primury or metastatic colorectal carcinoma, utilizing an intravenous administration of 1-4 mCi (1 mg) of 1311-B72.3 monoclotial antibody. Metastatic lesions were correctly identified in 418 patients by RIS. Two patients with small lesions (>2 cm diameter) had a false-negative RIS scan. Two patients had a true-negative RIS scan. Optimal images were obtained at I week peek postinjection. PCK studies showed that the plasma clearance of 131I-B72.3 was biexponetial with an alpha-phase half-life ranging from 0.5 to 7.1 hr and a beta-phase half-life ranging from 47.5 to 85.3 hr. Systemic and renal clearance data indicated that 131I-B72.3 was cleared very slowly and almost entirely by deiodination. This pilot study wus conducted to gain an understanding of the pharmacokinetics of this radiolabeled antibody. On the basis of these data, we are now studying second-generation antibodies as part of our long-range objectives to incorporate them in early detection and treatment protocols.

Original languageEnglish
Pages (from-to)129-134
Number of pages6
JournalCancer Investigation
Volume11
Issue number2
DOIs
StatePublished - 1993
Externally publishedYes

Fingerprint

Dive into the research topics of 'Radioimmunodetection of colorectal cancer metastases with 131i-labeled monoclonal antibody b72.3: A pilot study to determine efficacy of detection and pharmacokinetics'. Together they form a unique fingerprint.

Cite this